托尔瓦普坦的长期经验:肝毒性仍然是一个问题吗?
Pierre Antoine Brown1, Suzy Bubolic2, Annick Laplante2
1Division of Nephrology, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
托尔瓦普坦有效地减缓了自身主导多囊性病 (ADPKD) 的病进展. 在加拿大,频繁的肝脏监测在10年内在2800多名患者中预防了严重的肝损伤.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 自体主导多囊性病 (ADPKD) 是一种遗传性疾病,其特征是扩大和功能下降.
- 托尔瓦普坦 (JINARC®) 在加拿大被批准用于减缓ADPKD的进展.
- 在TEMPO 3:4研究中,Tolvaptan的使用表明存在潜在的肝损伤风险.
研究的目的:
- 审查tolvaptan在ADPKD患者中的肝脏安全性.
- 评估加拿大肝脏安全监测和分发计划 (HSMD) 的有效性.
- 评估托尔瓦诱导性肝损伤 (DILI) 的现实证据.
主要方法:
- 对托尔瓦普坦肝脏安全性的临床试验数据的审查.
- 来自加拿大HSMD计划的数据分析.
- 对用tolvaptan治疗的患者的现实世界证据的检查.
主要成果:
- 频繁的肝功能监测可以早期检测DILI.
- 及时停止治疗对于管理潜在的肝损伤至关重要.
- 在10年内,HSMD计划成功地预防了2800多名加拿大患者的严重肝损伤或肝衰竭,这些患者接受了托尔瓦普坦治疗.
结论:
- 托尔瓦普坦是减缓ADPKD进展的有价值的治疗方法.
- 强有力的安全监测计划对于管理药物诱导的肝损伤至关重要.
- 加拿大经验表明,当托尔瓦普坦与警的肝脏监测一起管理时,其安全性和有效性.
更多相关视频
08:25Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
相关概念视频
Hepatic Drug Excretion: Influencing Factors
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Desensitization and Tachyphylaxis
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
